Findings from the Drug Abuse Warning Network Immediate and Sustained Release Opioid Analgesics Judy K. Ball, Ph.D., M.P.A. Office of Applied Studies, Substance.

Slides:

Advertisements

Similar presentations

CESAR FAX U n i v e r s i t y o f M a r y l a n d, C o l l e g e P a r k A Weekly FAX from the Center for Substance Abuse Research February 4, 2013 Vol.

Advertisements

Trend in Prescription Drug Abuse In 2004, 19.1 million Americans were current illicit drug users (7.9% of the U.S. population) 1 In 2004, 19.1 million.

June 20, 2005 Pharmaceutical Misuse & Abuse: from National to Local What the Data Say and Mean for Montgomery County Public Schools Presenter: Kenneth.

10/20/ The Pharmaceutical Industry and Their Influence on Pain Management in the ED J. David Haddox, DDS, MD VP, Risk Management & Health Policy.

OPIOIDS I. Where do they come from? / synthesized in 1803

A Growing Problem…. We Will Discuss Prescription vs. OTC medications Alarming trends Myths about prescription drug abuse Specific medications of abuse.

CDER/CSS ALSDAC September 9-10, 2003 Risk Management and the Controlled Substances Act: The FDA Perspective Deborah B. Leiderman, M.D., M.A. Director Controlled.

San Francisco Bay Area Drug Trends and Effective Intervention Strategies Alice Gleghorn, Ph.D County Alcohol and Drug Program Administrator San Francisco.

National Institute on Drug Abuse P rescription D rug A buse: An Escalating Public Health Threat P rescription D rug A buse: An Escalating Public Health.

OVERDOSE SOLUTIONS 2013 OVERDOSE DATA FOR ALLEGHENY COUNTY Jennifer Janssen Manager Toxicology Laboratory Allegheny County Office of the Medical Examiner.

Findings from the Drug Abuse Warning Network Narcotic Analgesics Judy K. Ball, Ph.D., M.P.A. Office of Applied Studies, Substance Abuse and Mental Health.

Lock Your Meds BE AWARE. DON'T SHARE.. Your Home Medicine Cabinet: Does it look like this?

Sublingual Buprenorphine and Pain

Prescription Opioid Use and Opioid-Related Overdose Death — TN, 2009–2010 Jane A.G. Baumblatt, MD Centers for Disease Control and Prevention Epidemic Intelligence.

Lock Your Meds BE AWARE. DON'T SHARE. Sponsored by.

Serving our community by improving health The Addiction Crisis November 2014.

NAPHSIS Annual Meeting 2014Slide 1 NAPHSIS ANNUAL MEETING | Seattle | June 8-11, 2014 VITAL RECORDS: A CULTURE OF QUALITY Washington State’s approach to.

Abuse Liability of Hydromorphone Extended Release Capsules Silvia N. Calderon, Ph.D. Controlled Substance Staff Center for Drug Evaluation and Research.

1 National Estimates from the Drug Abuse Warning Network CAPT Kathy Poneleit United States Public Health Service Office of Applied Studies Substance Abuse.

Summary of Drug Abuse “Rates” in the United States: Focus on Morphine Catherine Dormitzer, PhD, MPH Division of Epidemiology Office of Surveillance and.

Situation analysis in Kyrgyzstan Making Opioids Available in Eastern Europe and Central Asia March 5-6, 2013 Vienna.

An Educational Perspective Based on Information Contained In The Indiana Prevention Resource Center Factline on Benzodiazepines ®

1 Mental Health and Substance Abuse Services Division Association of Substance Abuse Providers Mike Maples October 5, 2011.

March 2004 Prescription Drug Abuse in the United States.

1 Alcohol and Substance Abuse Council of Jefferson County, Inc. 167 Polk Street, Suite 320 Watertown, New York Voice: ; Fax: ;

Utah Emergency Medical Service Discharges Attributed to Opiate Use For Record Years

Opiates. Opiates: what, exactly are they?!? Opiates are used to induce sleep and alleviate pain. They act as depressants to the central nervous system.

Injury Surveillance Activities of the National Center for Injury Prevention and Control Data Issues Lee Annest, Ph.D. Director, Office of Statistics and.

Presented by Terance Woodworth, M.S. at the September 9, 2003 meeting of the Anesthetic and Life Support Drugs Advisory Committee.

CHEMICALS. DRUG DRUG ADDICTION DRUG DEPENDENCE.

1 Findings from the Drug Abuse Warning Network Judy K. Ball, Ph.D., M.P.A. Office of Applied Studies Substance Abuse and Mental Health Services Administration.

Buprenorphine Treatment for Opioid Dependence CESAR FAX U n i v e r s i t y o f M a r y l a n d, C o l l e g e P a r k A Weekly FAX from the Center for.

SOURCE: Treatment Episode Data Set (TEDS) 2005SOURCE: Treatment Episode Data Set (TEDS) 2005 Admissions to Substance Abuse Treatment for the Abuse of Opioid.

The National Crisis of Prescription Opiate Abuse: How can the FDA respond? Anesthetic & Life Support Drugs Advisory Committee March 29, 2007 Art Van Zee,MD.

The National Electronic Injury Surveillance System: Cooperative Adverse Drug Events Surveillance System (NEISS-CADES) Aaron B. Mendelsohn, PhD, MPH Office.

State of the State in outcomes: Prescription drug overdoses Karin A. Mack, PhD Senior Behavioral Scientist Prescription Drug Overdose Team National Center.

Opiate Management Douglas Keehn DO Adjunct Assistant Clinical Professor University Wisconsin Board Certified Anesthesia & Pain Management.

1 Prescribing Pain Medication – Guidelines for the Emergency Department April 22, 2012 Jennifer Sabel, PhD.

Risk Management of Modified- Release Opiate Analgesics: Palladone Sharon Hertz, M.D. Medical Team Leader, Analgesics Division of Anesthetic, Critical Care,

Increase in Methadone Related Deaths Lon R. Hays, M.D., M.B.A. Greg Davis, M.D.

1 National Estimates from the Drug Abuse Warning Network Judy K. Ball, Ph.D., M.P.A. Office of Applied Studies Substance Abuse and Mental Health Services.

Workshop 1: Building Local Quality Priorities. Primary Care: Visits Post Discharge WWLHIN rate of 40% 15/15 selected indicator (100%) Targeting 0 to 24.5%

1 Use of Pharmacotherapies by Substance Abuse Treatment Facilities November 2007 Cathie E. Alderks, PhD Substance Abuse and Mental Health Services Administration.

Mortality Associated with Dextromethorphan Elizabeth H. Crane, Ph.D., M.P.H. CAPT Kathy Poneleit, M.P.H. Office of Applied Studies, SAMHSA American Public.

Prescription Drug Monitoring Presented by: Len Abbott, Ph.D. Director Science and Technology Kathleen Valentine, General Manager PDM & Toxicology May 14,

DEBBIE DONELSON, MD Opioid use for nonmalignant pain management.

Gaston County Opioid Data

L484 oxycodone 10 mg oxycodone pill shapes 100 oxycodone pregnancy 2nd trimester nausea 10 mg oxycodone pill shapes description erowid tramadol oxycodone.

*Risk Evaluation and Mitigation Strategy

5th Annual Empowering Local Leadership Conference

Comparing abuse of extended-release versus immediate-release opioid analgesics adjusted for number of prescriptions and morphine-equivalent dose Stephen.

Methadone and Suboxone

Cabarrus County Substance Abuse

“Your life can change forever in a matter of seconds”.

Understanding the Opioid Epidemic

MEDICATION ASSISTED TREATMENT for OPIATE ADDICTION

Department of Health Management and Informatics

Controlled substance compliance

The European Experience: Prescription Drug Misuse in France, Germany, Italy and Spain 24 October 2017 Presented at Lisbon Addictions 2017 Jody L. Green,

National Prevention Week is an annual health observance dedicated to increasing public awareness of, and action around, substance abuse and mental health.

Pain Management: Patients Maintained on Buprenorphine

Prescription Drug Monitoring Program

The Euro-Drug Emergencies Network (Euro-DEN) ED presentations with acute toxicity related to the misuse of prescription medicines Professor Paul.

South Milwaukee Unite Against Drug Abuse

Alabama Community Care –Region A Round Table Discussion

Prescription Drug Monitoring Program

Calculating and Using Morphine Equivalent Doses of Opioids

Figure 1. National Drug Overdose Deaths Number Among All Ages, by Gender, Figure 1. National Drug Overdose Deaths—Number Among All Ages, by Gender,

Use of Opioid Analgesics Among Older Persons With Colorectal Cancer in Two Health Districts With Palliative Care Programs Judith Fisher, BSc (Pharm),

Situation analysis in Kyrgyzstan

Presentation transcript:

Findings from the Drug Abuse Warning Network Immediate and Sustained Release Opioid Analgesics Judy K. Ball, Ph.D., M.P.A. Office of Applied Studies, Substance Abuse and Mental Health Services Administration 9 September 2003

Emergency Departments  Stratified probability sample  Short-term, general, non-Federal hospitals operating 24-hour emergency departments  Representative estimates for coterminous U.S.  437 hospitals (80%) participated in 2002

DAWN Cases  Age 6-97 treated in ED  ED visit related to drug abuse  Abuse defined by patient’s motive for drug use –Dependence –Psychic effects –Suicide attempt/gesture

Drug Detail in DAWN  Illicit, prescription, OTC drugs  Specificity depends on medical record –Brand (trade) names – MSContin –Chemical names – morphine sulfate –Generic names – morphine –Classes – opiates –Street names  Multiple drugs per visit – drug “mentions”

Mentions of Selected Drugs in ED Visits Related to Drug Abuse Source: Drug Abuse Warning Network

ED Mentions of Opiates/Opioids, 2002 Fentanyl 1,506 Morphine 2,775 Unnamed Hydrocodone All others Oxycodone Source: Drug Abuse Warning Network

Narcotic Analgesics, by Type Type DrugIRSRUnspecified Unnamed Hydrocodone Hydromorphone Fentanyl Morphine Oxycodone

Unnamed Opiates, ED Mentions Source: Drug Abuse Warning Network

Hydrocodone, ED Mentions Source: Drug Abuse Warning Network

Hydromorphone, ED Mentions Source: Drug Abuse Warning Network

Fentanyl, ED Mentions Source: Drug Abuse Warning Network

Morphine, ED Mentions Source: Drug Abuse Warning Network

Oxycodone, ED Mentions Source: Drug Abuse Warning Network

Oxycodone, ED Mentions Source: Drug Abuse Warning Network

Oxycodone, ED Mentions Source: Drug Abuse Warning Network

Oxycodone, ED Mentions Source: Drug Abuse Warning Network

Oxycodone ED Mentions, IR 2002 SR IR 2001 SR IR 2000 SR IR 1999 SR IR 1998 SR IR

Drugs in Combination, 2002 FentanylHydrocodoneMorphineOxycodone Total visits 1,50625,1092,77520,748 Other drugs in visit: Multiple drugs 43%78%66%71% Major substance of abuse 16%43%38%44% Benzodiazepine 21%26%13%21% Other narcotic 17%14%27%18% Source: Drug Abuse Warning Network

Limitations of DAWN  Reportable cases of drug abuse, based on patient’s intent  Variable reporting of nonspecific terms  Cannot distinguish diversion vs. abuse with legitimate prescriptions  No information on health